Medical devices, healthcare technology and the business of care
PMA approval · P980016

VIRTUSO/ENTRUST/MAXIMO/INTRINSIC/MARQUIS/IMPLANTABLE CARDIVERTER DEFIBRILLATORS

Medtronic Cardiac Rhythm Disease Management · Decision date Oct 9, 1998

MEDTECHLEDGER EXPLANATIONP980016

What did the FDA approve?

The October 9, 1998 FDA statement records approval for the Medtronic Model 7271 GEM DR Dual Chamber Implantable Cardioverter Defibrillator System with Model 9960 application software, Model 6940 CapSureFix Lead, and Model 9466 Patient Magnet. The stated indication covers patients at risk of sudden death due to ventricular arrhythmias who have survived at least one cardiac arrest with loss of consciousness from ventricular tachyarrhythmia, or who have recurrent, poorly tolerated, sustained ventricular tachycardia.

The same dated statement notes that the clinical outcome for hemodynamically stable VT patients is not fully known and that safety and effectiveness studies have not been conducted for that group. The document does not describe trial data, labeling changes, or any relationship to a prior PMA. No supplement type or reason is supplied, so the specific regulatory action beyond the original approval cannot be characterized from the available fields.

FDA approval order statement

Approval for the Medtronic(R) Model 7271 GEM(TM) DR Dual Chamber Implantable Cardioverter Defibrillator System with Mdoel 9960 (GEM(TM) DR) Application Software, Medtronic(R) Model 6940 CapSureFix(R) Lead and Model 9466 Patient Magnet. This system is indicated for use in patients who are at risk of sudden death due to ventricular arrhythmias and have experienced one of the following situations: survival of at least one episode of cardiac arrest (manifested by loss of consciousness) due to ventricular tachyarrhythmia or recurrent, poorly tolerated, sustained ventricular tachycardia. (Note: the clinical outcome for hemodynamically stable VT patients is not fully known. Safety and effectiveness studies have not been conducted.)
Regulatory pathway
Original PMA
Clinical specialty
Cardiovascular
Decision date
Oct 9, 1998

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P980016
Regulatory pathway
Premarket approval application
Product code
LWS
Decision code
APPR
Decision date
Oct 9, 1998
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Implantable cardioverter defibrillator (non-CRT).

Product code
LWS
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P980016 received

    Application receipt date recorded by FDA.

  2. P980016 · FDA decision

    APPR

  3. P980016/S965 · Related supplement

    Cobalt MRI ICD, Cobalt XT MRI ICD, Crome MRI ICD

  4. P980016/S966 · Related supplement

    Cobalt MRI ICD (DDPB3Dl, DDPB3D4, DVPB3Dl, DVPB3D4); Cobalt XT MRI ICD (DDPA2Dl, DDPA2D4, DVPA2Dl, DVPA2D4); Crome MRI I

  5. P980016/S967 · Related supplement

    Cobalt MRI ICD, Cobalt XT MRI ICD, Crome MRI ICD

  6. P980016/S964 · Related supplement

    Cobalt MRI ICD (DDPB3D1, DDPB3D4, DVPB3D1, DVPB3D4); Cobalt XT MRI ICD (DDPA2D1, DDPA2D4, DVPA2D1, DVPA2D4); Crome MRI I

Timeline entries are records held by MedtechLedger for P980016. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P980016

Explore the linked device profile

Other records with product code LWS

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Medtronic Cardiac Rhythm Disease Management

Headquarters
Not reported
Brand website
medtronic.com
FDA applicant address
8200 Coral Sea St. N.E, Ms Mvs11, Mounds View, MN, 55112

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records